Raising HDL-cholesterol and lowering CHD risk: Does intervention work?

European Heart Journal, Supplement

Volumn 7, Issue F, 2005, Pages

  Shepherd, James ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular risk; Dyslipidaemia; HDL cholesterol

Indexed keywords

BEZAFIBRATE; CLOFIBRATE; DEXTROTHYROXINE; ESTROGEN; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; SIMVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; DEATH; DIET; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; GENE THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HUMAN; HYPOTHESIS; ISCHEMIC HEART DISEASE; LIFESTYLE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 32044436085     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui038     Document Type: Conference Paper

References (50)

1. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-714.
2. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-741.
3. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113.
4. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-2838.
5. Assmann G, Schulte H, von Eckardstein A et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl.):S11-S20.
6. Gordon DJ, Probstfield JL, Garrison RJ. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15.
7. Lacko AG, Barter P, Ehnholm C et al. International symposium on basic aspects of HDL metabolism and disease prevention. J Lipid Res 2000;41:1695-1699.
8. Barter PJ, Nicholls S, Rye KA. Antiinflammatory properties of HDL. Circ Res 2004;95:764-772.
9. Garrison RJ, Wilson PW, Castelli WP et al. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism 1980;29:1053-1060.
10. Wilson PW, Anderson KM, Harris T et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994;49:M252-M257.
11. Ellison RC, Zhang Y, Qureshi MM et al. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J 2004;147:529-535.
12. Jansen DF, Nedeljkovic S, Feskens EJ et al. Coffee consumption, alcohol use, and cigarette smoking as determinants of serum total and HDL cholesterol in two Serbian cohorts of the Seven Countries Study. Arterioscler Thromb Vasc Biol 1995;15:1793-1797.
13. Chambless L, Doring A, Filipiak B et al. Determinants of HDL-cholesterol and the HDL-cholesterol/total cholesterol ratio. Results of the Lubeck Blood Pressure Study. Int J Epidemiol 1990;19:578-585.
14. Garrison RJ, Kannel WB, Feinleib M et al. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis 1978;30:17-25.
15. Martinez-Gonzalez MA, Fernandez-Garcia J, Sanchez-Izquierdo F et al. Life-style factors associated with changes in serum lipids in a follow-up study of cardiovascular risk factors. Eur J Epidemiol 1998;14:525-533.
16. Couillard C, Despres JP, Lamarche B et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the Health, Risk Factors, Exercise Training and Genetics (HERITAGE) Family Study. Arterioscler Thromb Vasc Biol 2001;21:1226-1232.
17. Stefanick ML, Mackey S, Sheehan M et al. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 1998;339:12-20.
18. Williams PT, Stefanick ML, Vranizan KM et al. The effects of weight loss by exercise or by dieting on plasma high-density lipoprotein (HDL) levels in men with low, intermediate, and normal-to-high HDL at baseline. Metabolism 1994;43:917-924.
19. Cauley JA, Kriska AM, LaPorte RE et al. A two year randomized exercise trial in older women: effects on HDL-cholesterol. Atherosclerosis 1987;66:247-258.
20. Avenell A, Brown TJ, McGee MA et al. What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions. J Hum Nutr Diet 2004;17:293-316.
21. Stefanick ML. Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc 1999;31:S609-S618.
22. Duverger N, Kruth H, Emmanuel F et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996;94:713-717.
23. Vergnes L, Baroukh N, Ostos MA et al. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis. Arterioscler Thromb Vasc Biol 2000;20:2267-2274.
24. Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res 2000;41:853-872.
25. Franceschini G, Sirtori CR, Capurso A II et al. A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900.
26. Weisgraber KH, Bersot TP, Mahley RW et al. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 1980;66:901-907.
27. Gualandri V, Franceschini G, Sirtori CR et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985;37:1083-1097.
28. Sirtori CR, Calabresi L, Franceschini G et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001;103:1949-1954.
29. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300.
30. Rubins HB, Robins SJ, Iwane MK et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52.
31. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
32. Robins SJ, Collins D, Wittes JT et al. VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomised controlled trial. JAMA 2001;285:1585-1591.
33. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162:2597-2604.
34. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
35. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651.
36. Bezafibrate Infarction Prevention Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27.
37. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381.
38. Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-1104.
39. Canner PL, Berge KG, Wenger NK et al. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
40. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5-S10.
41. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from Coronary Drug Project. Circulation 2002;106:II-636.
42. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality similarly in patients with and without metabolic syndrome. J Am Coll Cardiol 2003;41(Suppl. A):291A.
43. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
44. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
45. Ballantyne CM, Herd JA, Ferlic LL et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-743.
46. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
47. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445.
48. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88:14N-18N.
49. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25:649-663.
50. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-1398.